The FDA has recently approved Osimertinib for the treatment of patients with metastatic T790 M mutation-positive non-small cell lung cancer (NSCLC) based on the evidence of the AURA3 trial where progression-free survival benefit was observed in both progressive NSCLC following first-line EGFR TKI therapy and EGFR T790 M mutation-positive NSCLC identified by the cobas EGFR mutation test [10, 11]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.